<DOC>
	<DOCNO>NCT01477242</DOCNO>
	<brief_summary>The purpose study evaluate anti-emetic effect oral ondansetron . For evaluation , investigator perform multi-center , double-blind , placebo-controled , randomize study . The investigator assumption oral ondansetron prior intramuscular ketamine reduce occurrence ketamine-induced vomiting .</brief_summary>
	<brief_title>The Effect Ondansetron During Intramuscular Ketamine Use Children : A Trial Emergency Department</brief_title>
	<detailed_description>Methods - multi-center , double-blind , placebo-controled , randomize study ( 4 tertiary hospital ED ) - survey occurrence vomit ED discharge Primary outcome - number vomit ED home Secondary outcome - parent 's satisfaction ED length stay</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>child 18 year age child plan admit ketamine intramuscular injection child ASA classification class I II n't want enroll study child condition contraindication ketamine ( IICP , IIOP , psychosis , brain tumor , thyroid disease , porphyria ) child condition contraindication ondansetron ( hypersensitivity 5HT3 antagonist , Long QT syndrome , severe liver failure , obstructive ileus ) child 3 month age child whose weight 30 kg child manage drug ketamine</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>vomit</keyword>
	<keyword>anti-emetics</keyword>
	<keyword>ketamine</keyword>
	<keyword>sedation</keyword>
</DOC>